HAWTHORNE, N.J.--(BUSINESS WIRE)--Proteonomix, Inc. (OTCBB: PROT), a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives, today announced the termination of the Research Agreement and Phase 1 clinical trial with the University of Miami. This agreement is related to the Company’s compound UMK-121 for End Stage Liver Disease (ESLD) and was entered into on November 15, 2011.
